Jardiance Reduces Cardiovascular Mortality Risk in Type 2 Diabetes

University of Toronto researchers recently examined the benefits of the diabetes drug Jardiance. Their aim was to see how the drug might benefit patients with both type 2 diabetes and peripheral artery disease.

During the study, researchers examined type 2 diabetes patients with and without peripheral artery disease. They found that both groups experienced reductions in heart failure hospitalizations, cardiovascular mortality, and diabetic neuropathy after taking the drug for an average of 3.1 years. This was in comparison to the group of participants who took a placebo.

The researchers concluded that the study has important implications for risk-reduction approaches in patients with both diabetes and peripheral artery disease.

These findings were published in Circulation on November 13, 2017.